Valneva: Marketing authorization application deemed admissible by the EMA

(CercleFinance.com) - Valneva has announced that the European Medicines Agency (EMA) has accepted its marketing authorization application (MAA) for its single-dose chikungunya vaccine candidate VLA1553.


The chikungunya virus, or CHIKV, has already spread to over 110 countries, and the risk of chikungunya spreading to Europe is relatively high due to the possibility of infected travellers", stresses Juan Carlos Jaramillo, Valneva's Chief Medical Officer.

VLA1553 was approved by the US FDA in early November under the brand name Ixchiq. In mid-November, Valneva also announced positive results from a pivotal Phase III immunogenicity study in adolescents.

Copyright (c) 2023 CercleFinance.com. All rights reserved.